TELA Bio CEO Heather Getz Receives 2.87M-Share Equity Awards

What Happened
Heather C. Getz, Chief Executive Officer of TELA Bio, Inc. (TELA), received three equity awards on August 3, 2026: a grant of 500,000 restricted stock units (RSUs) and two derivative awards covering 1,365,000 and 1,005,000 shares, respectively. All awards were granted at $0.00 exercise/price (compensation grants rather than open‑market purchases or sales). In total the awards cover 2,870,000 shares (or share equivalents) and will vest over future service‑based schedules described below.

Key Details

• Transaction date: August 3, 2026; Form 4 filed August 5, 2026 (timely filing).
• Awards: 500,000 RSUs (grant at $0.00); 1,365,000 and 1,005,000 derivative awards (granted at $0.00).
• Vesting: F1 — the 500,000 RSUs vest in four equal annual installments beginning August 3, 2027, subject to continued service. F2 — the option/derivative vests 25% on August 3, 2027, with the remaining 75% vesting in equal monthly installments over the following 36 months, subject to continued service.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Filing timeliness: filed within the normal Form 4 reporting window (no late‑filing indication).

Context
These entries are compensation grants (awards/derivative grants), not open‑market purchases or sales. Such grants are commonly used to align executive incentives and do not by themselves indicate an immediate cash flow or a decision to sell shares. The derivative awards will convert to common shares only as they vest under the stated schedules and subject to continued employment.